Vitrolife AB/Skr VITR
1D1W1MYTD1Y5YMAX
Capital at risk
About Vitrolife AB
Vitrolife AB is a biotechnology company that operates in the fertility treatment industry, providing products and services designed to support in vitro fertilization (IVF). The company's portfolio includes culture media, IVF disposable devices, and time-lapse systems for embryo assessment. Founded in 1994, Vitrolife has developed a strong presence in the field of reproductive health by focusing on improving clinical results and patient outcomes. Headquartered in Gothenburg, Sweden, the company serves customers globally, with manufacturing facilities and offices across Europe, the Americas, and Asia. Vitrolife's strategic focus on research and development, along with its commitment to quality and innovation, positions it as a significant player in the global IVF market.
- Ticker
- Skr VITR
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 1,103
- Headquarters
- Gothenburg, Sweden
- Website
- www.vitrolife.com
Vitrolife AB Metrics
BasicAdvanced
kr 12B
-
-kr 36.80
1.72
kr 1.10
1.22%
Price and volume
Market cap
kr 12B
Beta
1.72
52-week high
kr 153.50
52-week low
kr 84.00
Average daily volume
280K
Dividend rate
kr 1.10
Financial strength
Current ratio
3.641
Quick ratio
2.76
Long term debt to equity
0.191
Total debt to equity
0.197
Interest coverage (TTM)
9.16%
Profitability
EBITDA (TTM)
988
Gross margin (TTM)
59.23%
Net profit margin (TTM)
-146.99%
Operating margin (TTM)
18.64%
Effective tax rate (TTM)
-2.74%
Revenue per employee (TTM)
kr 3,070,000
Management effectiveness
Return on assets (TTM)
2.81%
Return on equity (TTM)
-46.53%
Valuation
Price to revenue (TTM)
3.611
Price to book
1.5
Price to tangible book (TTM)
-69.13
Price to free cash flow (TTM)
22.629
Free cash flow yield (TTM)
4.42%
Free cash flow per share (TTM)
3.995
Dividend yield (TTM)
1.22%
Forward dividend yield
1.22%
Growth
Revenue change (TTM)
-4.26%
Earnings per share change (TTM)
-1,198.39%
3-year revenue growth (CAGR)
-0.22%
10-year revenue growth (CAGR)
15.97%
3-year earnings per share growth (CAGR)
134.17%
10-year earnings per share growth (CAGR)
35.19%
3-year dividend per share growth (CAGR)
8.97%
10-year dividend per share growth (CAGR)
8.65%
Bulls say / Bears say
Q2 2026 EBITDA margin surged to 34.4% from 27.8%, driven by disciplined cost control, portfolio rationalisation and one-time VAT reversals, boosting overall profitability (MFN.se)
The board launched a SEK 500 million share buyback programme effective July 17, 2026, through the next AGM to optimise capital structure and enhance shareholder value (Stockopedia)
In Q1 2026, organic sales grew by 9% in Consumables and 11% in Technologies, indicating strong demand for core IVF products and technological solutions (Cision)
Total Q2 2026 sales decreased 2% in SEK to SEK 857 million, with organic growth excluding exited product lines of just 1%, underscoring persistent revenue headwinds (FinancialFilings)
CEO Bronwyn Brophy O'Connor announced her decision to leave the company on May 22, 2026, and the board has initiated a recruitment process, introducing potential leadership uncertainty (TradingView)
Sales in the Genetics segment fell 2% in Q2 2026 and 1% in Q1 2026, highlighting ongoing challenges in scaling higher-margin Genetics products (FinancialFilings, Cision)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
Upcoming events
No upcoming events
Funds containing Vitrolife AB
AllEURGBPUSD
Fund name | Fund size | Skr VITR weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.04% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.04% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.